MESOMARK™: A Potential Test for Malignant Pleural Mesothelioma
- 1 April 2007
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 53 (4), 666-672
- https://doi.org/10.1373/clinchem.2006.079327
Abstract
Background: Soluble mesothelin-related peptides (SMRP)have been reported to be potential biomarkers for malignant pleural mesothelioma (MPM). We report analytical and preliminary clinical studies of MESOMARK™, a quantitative assay for SMRP. Methods: The MESOMARK assay is a 2-step immunoenzymatic assay in an ELISA format with a 6-point calibration curve (0–32 nmol/L). We assessed analytical imprecision, analyte stability, and analytical interferences. We measured SMRP by this assay in 409 apparently healthy individuals (reference interval study), 177 patients with nonmalignant conditions, and 500 cancer patients, including 88 with MPM. Results: The limit of detection was 0.16 nmol/L. At 2–19 nmol/L, intraassay imprecision (CV) was 1.1%–5.3%, and total imprecision was 4.0%–11.0%. The mean dilution recovery for 5 samples was 109% (range, 99%–113%). No interference was seen from added bilirubin (200 mg/L), hemoglobin (500 mg/L), triglycerides (30 g/L), chemotherapeutic agents, or other tested substances. Recombinant mesothelin was stable in serum upon freeze/thaw at −70 °C and upon storage for at least 7 days at 2–8 °C. The 99th percentile of the reference group was 1.5 nmol/L [95% confidence interval (CI), 1.2–1.6 nmol/L; n = 409], and mean SMRP was significantly higher in sera from patients with MPM (7.5 nmol/L; 95% CI, 2.8–12.1 nmol/L; n = 88). SMRP was increased in 52% and 5% of MPM patients and asbestos-exposed individuals, respectively. Concentrations in other nonmalignant and malignant conditions were similar to those in healthy controls. Conclusions: The MESOMARK assay is analytically robust and may be useful for the detection and management of mesothelioma.Keywords
This publication has 15 references indexed in Scilit:
- Mesothelin Variant 1 Is Released from Tumor Cells as a Diagnostic MarkerCancer Epidemiology, Biomarkers & Prevention, 2006
- Advances in the diagnosis, evaluation, and management of malignant pleural mesotheliomaRespirology, 2005
- Characterization of human mesothelin transcripts in ovarian and pancreatic cancerBMC Cancer, 2004
- Pathogenesis of Malignant MesotheliomaClinical Lung Cancer, 2004
- Mesothelin-family proteins and diagnosis of mesotheliomaThe Lancet, 2003
- Application of Mesothelin Immunostaining in Tumor DiagnosisThe American Journal of Surgical Pathology, 2003
- The pathogenesis of mesotheliomaSeminars in Oncology, 2002
- Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinomaProceedings of the National Academy of Sciences, 1999
- Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proceedings of the National Academy of Sciences, 1996
- The Pathogenesis of Asbestos-Associated DiseasesNew England Journal of Medicine, 1982